Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02942498
Other study ID # SXF2-8
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date July 2016
Est. completion date October 31, 2018

Study information

Verified date September 2016
Source Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine vitamin C and vitamin E in combination are effective in the treatment of cognitive and behavior disorder in children with fragile X syndrome.


Description:

The combination of vitamin E and vitamin C supplementation has been associated with a lower prevalence (-78%) and incidence (-64%) of Alzheimer's disease in the elderly population. It has recently been shown that dietary vitamin E supplementation reduces the production of free radicals inhibiting NADPH oxidase activity in circulating neutrophils. Another work describes the inhibition of glutamate release by activated microglia in cell cultures incubated with vitamin E, effect that can prevent excitotoxicity. The investigators propose to evaluate the effectiveness of treatment in neurodevelopmental disorders affected by fragile X syndrome (FXS) with lipophilic compounds antioxidants such as tocopherol and hydrophilic compounds antioxidants such as ascorbic acid, which regulate oxidative stress and improve learning and behavioral mouse model and humans. Our group has positive results in the use of this combination of antioxidants as a treatment for fragile X syndrome in adolescents. This disease has developed previous clinical trials with EUDRACT codes: 2009-017837-23 and 2013-004276-35. The use of the combination of vitamin C and E in the treatment of cognitive and behavioral disorder in FXS, is patented PCT-050 187 with reference number 2011070875 This combination will be administered as a single oral dose with a total dose of 10mg / kg / day for each of the vitamins. This dose is maintained within the therapeutic range of both antioxidants.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date October 31, 2018
Est. primary completion date September 25, 2017
Accepts healthy volunteers No
Gender All
Age group 1 Year to 8 Years
Eligibility Inclusion Criteria: 1. Diagnosis of Fragile X syndrome by genetic testing of molecular biology, full mutation result methylation. 2. Having an older age of 1 year and less than 9 years 3. Having signed the informed consent document before starting their participation in the trial. Exclusion Criteria: 1. Any advanced, severe or unstable disease. 2. Individuals with other psychiatric diagnosis as the first diagnosis. 3. It have been suffered serious medical problems in the last 12 months. 4. Be taking more than 100 mg of vitamin E or C a day in the last month. 5. Having physical, mental or sensory impairments that prevent the assessment of effectiveness. 6. Hypersensitivity to any component of the preparation. 7. Liver failure or severe renal or previous history of kidney stones. 8. Any treatment regimen, including treatment with psychotropic drugs and / or anticonvulsant therapy that has not been stable for a period = 4 weeks before randomization. 9. Current treatment with more than two psychoactive medications, excluding medication used specifically for the control of seizures. 10. Hypoprothrombinemia secondary to vitamin K deficiency 11. Sensitivity to any of the compounds of formula treatment. 12. Patients diagnosed with congenital or idiopathic methemoglobinemia for diagnosis of glucose-6-phosphate dehydrogenase deficiency. 13. Use of oral anticoagulants, iron or vitamin A. 14. Forecast initiate or change pharmacological or no pharmacological interventions during the course of the study. 15. Patients weighing less than 4.2 kg

Study Design


Intervention

Drug:
Vitamin C 10mg/Kg Vitamin E 10 mg/Kg

Placebo
Placebo

Locations

Country Name City State
Spain Hospital Regional de Málaga Malaga Málaga

Sponsors (2)

Lead Sponsor Collaborator
Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud Delos Clinical

Country where clinical trial is conducted

Spain, 

References & Publications (3)

Barger SW, Goodwin ME, Porter MM, Beggs ML. Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem. 2007 Jun;101(5):1205-13. Epub 2007 Mar 30. — View Citation

Castilla P, Dávalos A, Teruel JL, Cerrato F, Fernández-Lucas M, Merino JL, Sánchez-Martín CC, Ortuño J, Lasunción MA. Comparative effects of dietary supplementation with red grape juice and vitamin E on production of superoxide by circulating neutrophil NADPH oxidase in hemodialysis patients. Am J Clin Nutr. 2008 Apr;87(4):1053-61. — View Citation

Zandi PP, Anthony JC, Khachaturian AS, Stone SV, Gustafson D, Tschanz JT, Norton MC, Welsh-Bohmer KA, Breitner JC; Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol. 2004 Jan;61(1):82-8. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Autism Treatment Evaluation Checklist (ATEC). 32 weeks
Primary Global Clinical Impression (GCI) 32 weeks
Primary Peabody Picture Vocabulary Test (PiVT) 32 weeks
Primary Battelle developmental inventory screening 32 weeks
Primary Vineland Adaptive Behavior Scales 32 weeks
Primary Adverse event reported 32 weeks
Primary Quantitative Checklist for Autism in Toddlers (Q-Chat) test 32 weeks
Secondary Golberg scale GHQ-28 32 weeks
Secondary Quality life SF36 test 32 weeks
Secondary Psychological General Well-Being Index 32 weeks
Secondary Sleep Disturbance Scale for Children 32 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04768803 - Ghrelin in Patients With a Rare Disease Associated With Intellectual Disability, and Hyperphagia, and/or Overweight, and/or Obesity